Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • organ fibrosis
    • HGF/c-met pathway
  • pipeline
    • ANG-3070
    • ANG-3777
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
      • historic price lookup
    • analyst coverage
    • press releases
    • events & presentations
    • sec filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

RSL-ALI

July 1, 2020February 5, 2021

Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment (Johnson & Mathay)

Posted in RSL-ALI
July 1, 2020February 5, 2021

Acute respiratory distress syndrome: epidemiology and management approaches (Walkey, et al)

Posted in RSL-ALI
July 1, 2020February 5, 2021

Cost and Healthcare Utilization in ARDS – Different from Other Critical Illness? (Bice, et al)

Posted in RSL-ALI

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2022 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | BOSTON | AUSTRALIA